With any laboratory service, attention to detail is of the utmost importance. At Xeno we put the same attention into our research studies as we do in our routine clinical work.
Indianapolis, IN (PRWEB) December 17, 2014
Xeno Diagnostics has again received an award for Laboratory Excellence following its most recent COLA inspection. Xeno has met all criteria for Laboratory Accreditation by COLA, a national healthcare accreditation organization. Accreditation is earned only by laboratories that apply rigid standards of quality in day-to-day operations, demonstrate continued accuracy in the performance of proficiency testing, and pass a rigorous on-site laboratory survey.
While the Laboratory Excellence award reflects Xeno’s capabilities in handling clinical laboratory testing, Xeno’s President, Dan Follas, explains how this award also reflects the high quality of their research services: “With any laboratory service, attention to detail is of the utmost importance. At Xeno we put the same attention into our research studies as we do in our routine clinical work.”
The Laboratory Excellence award received from COLA caps a strong performance in 2014 for Xeno, which saw a significant increase in its client base, as well as the addition of Dr. Daniel Wierda as their Director of Research and Development. Xeno’s success in performing complex cell-based assays and their firm grounding in clinical testing make them a great addition to Indiana’s growing biotechnology industry.
About Xeno Diagnostics:
Xeno Diagnostics was founded in 2007, with the mission of making more products and services available for researchers studying porcine models of disease and inflammation. Early focus on porcine models included the development of antibodies, test procedures, and functional cell-based assays. However, clients also requested cell-based assays in other animal models. Xeno quickly adapted, and now offers assays for many species, including non-human primates (baboon, cynomolgus macaque, and rhesus macaque) bovine, and human. At present, Xeno now focuses on providing high-quality, GLP compliant cell-based assays. These assays are of particular interest to organizations looking to move their products or technologies through the regulatory landscape. Xeno has found great success in being able to provide solutions for the unique challenges faced by organizations involved in transplantation research and medical device development. To learn more about Xeno Diagnostics and their contract research services, visit http://www.xenodiagnostics.com.